Education
About Us
Working with TipRanks
Follow Us
Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
CNTA Stock Chart & Stats
$27.54
-$0.91(-5.25%)
At close: 4:00 PM EST
$27.54
-$0.91(-5.25%)
Day’s Range― - ―
52-Week Range$9.60 - $29.33
Previous CloseN/A
Volume658.98K
Average Volume (3M)1.75M
Market Cap
$3.76B
Enterprise Value$3.13B
Total Cash (Recent Filing)$246.21M
Total Debt (Recent Filing)$118.26M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 26, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding146,075,740
10 Day Avg. Volume3,567,699
30 Day Avg. Volume1,753,596
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.78
Price to Sales (P/S)0.00
P/FCF Ratio-13.49
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue208.37
Enterprise Value/Gross Profit211.59
Enterprise Value/Ebitda-13.75
Forecast
1Y Price Target
$37.10Price Target Upside34.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy Of ORX750Centessa's ORX750 achieves a slightly greater MWT score compared to Alkermes' results, despite a significantly shorter duration on the drug.
Market PotentialCNTA's early data supports ORX750 as a potential best-in-class therapy, strengthening its market potential across NT1, NT2, and IH.
Safety ProfileThe safety and tolerability profile of ORX750 is generally favorable, which is encouraging for its development.
Bears Say
Financial ConstraintsYears of cash left is approximately 2.0, which suggests financial constraints may soon become a concern.
Financial SustainabilityAnnualized cash burn of $166.4 million indicates a high rate of expenditure, raising potential financial sustainability issues.
MWT ScoresMWT scores appear to be decreasing with expansion from NT1 and into NT2.
Centessa Pharmaceuticals News
CNTA FAQ
What was Centessa Pharmaceuticals’s price range in the past 12 months?
Centessa Pharmaceuticals lowest stock price was $9.60 and its highest was $29.33 in the past 12 months.
What is Centessa Pharmaceuticals’s market cap?
Centessa Pharmaceuticals’s market cap is $3.76B.
When is Centessa Pharmaceuticals’s upcoming earnings report date?
Centessa Pharmaceuticals’s upcoming earnings report date is Mar 26, 2026 which is in 124 days.
How were Centessa Pharmaceuticals’s earnings last quarter?
Centessa Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.022.
Is Centessa Pharmaceuticals overvalued?
According to Wall Street analysts Centessa Pharmaceuticals’s price is currently Undervalued.
Does Centessa Pharmaceuticals pay dividends?
Centessa Pharmaceuticals does not currently pay dividends.
What is Centessa Pharmaceuticals’s EPS estimate?
Centessa Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Centessa Pharmaceuticals have?
Centessa Pharmaceuticals has 146,075,740 shares outstanding.
What happened to Centessa Pharmaceuticals’s price movement after its last earnings report?
Centessa Pharmaceuticals reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -5.139%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals?
Currently, no hedge funds are holding shares in CNTA
Centessa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.10 (34.71% Upside)
$37.10 (34.71% Upside)
Blogger Sentiment
Bullish
CNTA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 142.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.36%
12-Months-Change
Fundamentals
Return on Equity
-60.45%
Trailing 12-Months
Asset Growth
-26.47%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals
Centessa Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative medicines for a wide range of diseases. The company operates in the pharmaceuticals sector, with a portfolio encompassing diverse therapeutic areas such as oncology, hematology, and rare diseases. Centessa leverages a unique 'asset-centric' research model that prioritizes the development of high-potential drug candidates through a network of subsidiary companies, each focused on distinct therapeutic areas.
CNTA Stock 12 Month Forecast
Average Price Target
$37.10
▲(34.71% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
Ownership Overview
1.15% Insiders
10.30% Mutual Funds
72.85% Other Institutional Investors
15.22% Public Companies and
Individual Investors